Clinical Trials Logo
  1. Home
  2. Premenopausal Breast Cancer
  3. NCT01546649

A Phase 3 Comparative Study of TAP-144-SR(6M) in Postoperative and Hormone Therapy-naïve Patients With Premenopausal Breast Cancer

Premenopausal Breast Cancer Clinical Trial

Clinical Trial Summary

Hormone dynamics, pharmacokinetics, safety, and efficacy of TAP-144-SR(6M) will be evaluated against TAP-144-SR(3M) in postoperative and hormone therapy-naïve patients with premenopausal breast cancer

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01546649
Study type Interventional
Source Takeda
Contact
Status Completed
Phase Phase 3
Start date April 2012
Completion date December 2014
View Details
See also
  Status Clinical Trial Phase
Terminated NCT01726322 - Ovarian Reserve in Premenopausal Breast Cancer
Terminated NCT02990845 - Pembrolizumab and Exemestane/ Leuprolide in Premenopausal HR+/ HER2- Locally Advanced or Metastatic Breast Cancer Phase 1/Phase 2
Recruiting NCT05982093 - Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer Phase 2
Active, not recruiting NCT04997941 - Higher Dose Preoperative taMOxifen in Premenopausal bREast Cancer Patients Phase 2
Recruiting NCT06458764 - Sexual Dysfunction Check-up in Premenopausal Breast Cancer Survivors Taking Endocrine Therapy: A Cross-Sectional Study
Completed NCT03209518 - Special Drug Use Surveillance of Leuprorelin for Injection Kit 22.5 mg in "Premenopausal Breast Cancer"
Not yet recruiting NCT05801705 - Comparative Evaluation of Efficacy and Safety of Toremifene, Tamoxifen, and Aromatase Inhibitor Plus Ovarian Function Suppression in Hormone Receptor-Positive Early Breast Cancer Among Non-Low-Risk Premenopausal Women: A Real-World Study
Active, not recruiting NCT03407768 - Role of Individualized Intervention(s) in Hormone-Receptor Positive Early-stage Breast Cancer N/A
Recruiting NCT05720260 - Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC Phase 2
Recruiting NCT05333328 - OFS in Premenopausal Node+ Breast Cancer With Low Genomic Risk Phase 4
Not yet recruiting NCT06225284 - Neoadjuvant Chemotherapy With or Without GnRH Agonist for Premenopausal Triple-negative Early Breast Cancer Patients Phase 2